Sexual & Reproductive Health

Cervical cancer vaccine produces high anti-HPV immune response in adolescents

Published in Women's Health Weekly, June 16th, 2005

Gardasil, Merck & Co., Inc.'s, investigational quadrivalent human papillomavirus (HPV) vaccine, produced higher anti-HPV immune responses among adolescent males and females compared to young women, according to a recent study.

Gardasil is an investigational vaccine designed to prevent infection from four common HPV types - 16, 18, 6, and 11 - and related cervical cancer, cervical precancers, and genital warts. These data from a phase III study of Gardasil were presented for the first time at the annual meeting of the European Society of Pediatric Infectious Diseases (ESPID). This is the first trial to evaluate the immune responses and tolerability among young...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-06-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry